Donor-Derived Infections: Incidence, Prevention, and Management

Chapter

Abstract

Organ donors reflect the diverse US population, and there are an increasing number of donors born in, who have resided in, or who have traveled to underdeveloped areas of the world or areas with geographically restricted infections. As such, these donors are exposed to pathogens that can potentially be transmitted to recipients of the donor’s organs. Additionally, there are newer techniques to identify many pathogens that may be transmitted from the donor to the transplant recipients. Finally, high-profile reports of several donor-derived infections have heightened awareness of donor-derived infections and have likely contributed to increased recognition. In this chapter, the incidence, methods of identification and prevention, and management of unexpected donor-derived infections will be reviewed.

Keywords

Donor-derived infection Donor-derived transmission Organ donor screening Increased risk donor Endemic infection 

References

  1. 1.
    Sayegh MH, Carpenter CB. Transplantation 50 years later—progress, challenges, and promises. N Engl J Med. 2004;351(26):2761–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Green M. Introduction: infections in solid organ transplantation. Am J Transplant. 2013;13 Suppl 4:3–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Tuttle-Newhall JE, Krishnan SM, Levy MF, McBride V, Orlowski JP, Sung RS. Organ donation and utilization in the United States: 1998-2007. Am J Transplant. 2009;9(4 Pt 2):879–93.PubMedCrossRefGoogle Scholar
  4. 4.
    Port FK, Merion RM, Roys EC, Wolfe RA. Trends in organ donation and transplantation in the United States, 1997-2006. Am J Transplant. 2008;8(4 Pt 2):911–21.PubMedCrossRefGoogle Scholar
  5. 5.
    Fishman JA, Greenwald MA, Kuehnert MJ. Enhancing transplant safety: a new era in the microbiologic evaluation of organ donors? Am J Transplant. 2007;7(12):2652–4.PubMedCrossRefGoogle Scholar
  6. 6.
    Caliendo AM, Lake JR. Is it risky to use kidneys from CDC-increased risk donors? Am J Transplant. 2007;7(6):1437–8.PubMedCrossRefGoogle Scholar
  7. 7.
    West Nile virus infections in organ transplant recipients—New York and Pennsylvania, August-September, 2005. Morb Mortal Wkly Rep. 2005;54(40):1021–3.Google Scholar
  8. 8.
    Transplantation-transmitted tuberculosis—Oklahoma and Texas, 2007. Morb Mortal Wkly Rep. 2008;57(13):333–6.Google Scholar
  9. 9.
    Bowen 2nd PA, Lobel SA, Caruana RJ, Leffell MS, House MA, Rissing JP, et al. Transmission of human immunodeficiency virus (HIV) by transplantation: clinical aspects and time course analysis of viral antigenemia and antibody production. Ann Intern Med. 1988;108(1):46–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Gupta S, Markham DW, Mammen PP, Kaiser P, Patel P, Ring WS, et al. Long-term follow-up of a heart transplant recipient with documented seroconversion to HIV-positive status 1 year after transplant. Am J Transplant. 2008;8(4):893–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Iwamoto M, Jernigan DB, Guasch A, Trepka MJ, Blackmore CG, Hellinger WC, et al. Transmission of West Nile Virus from an organ donor to four transplant recipients. N Engl J Med. 2003;348(22):2196–203.PubMedCrossRefGoogle Scholar
  12. 12.
    Nampoory MR, Gupta RK, Johny KV, Costandi JN, Samhan M, Ninan VT, et al. Organ-transmitted HCV infection in kidney transplant recipients from an anti-HCV negative donor. Transplant Proc. 1999;31(8):3207–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Palacios G, Druce J, Du L, Tran T, Birch C, Briese T, et al. A new arenavirus in a cluster of fatal transplant-associated diseases. N Engl J Med. 2008;358(10):991–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Quarto M, Germinario C, Fontana A, Barbuti S. HIV transmission through kidney transplantation from a living related donor. N Engl J Med. 1989;320(26):1754.PubMedGoogle Scholar
  15. 15.
    Srinivasan A, Burton EC, Kuehnert MJ, Rupprecht C, Sutker WL, Ksiazek TG, et al. Transmission of rabies virus from an organ donor to four transplant recipients. N Engl J Med. 2005;352(11):1103–11.PubMedCrossRefGoogle Scholar
  16. 16.
    Fischer SA, Graham MB, Kuehnert MJ, Kotton CN, Srinivasan A, Marty FM, et al. Transmission of lymphocytic choriomeningitis virus by organ transplantation. N Engl J Med. 2006;354(21):2235–49.PubMedCrossRefGoogle Scholar
  17. 17.
    Ison MG, Llata E, Conover CS, Friedewald JJ, Gerber SI, Grigoryan A, et al. Transmission of human immunodeficiency virus and hepatitis C virus from an organ donor to four transplant recipients. Am J Transplant. 2011;11(6):1218–25.PubMedCrossRefGoogle Scholar
  18. 18.
    HIV transmitted from a living organ donor—New York City, 2009. Morb Mortal Wkly Rep. 2011;60(10):297–301.Google Scholar
  19. 19.
    Transmission of hepatitis C virus through transplanted organs and tissue—Kentucky and Massachusetts, 2011. Morb Mortal Wkly Rep. 2011;60(50):1697–1700.Google Scholar
  20. 20.
    Seem DL, Lee I, Umscheid CA, Kuehnert MJ, Service USPH. PHS guideline for reducing human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission through organ transplantation. Public Health Rep. 2013;128(4):247–343.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Echenique IA, Cohen D, Rudow DL, Ison MG. Impact of repeat testing of living kidney donors within 14 days of the transplant procedure: a multicenter retrospective survey. Transpl Infect Dis. 2014;16(3):403–11.PubMedCrossRefGoogle Scholar
  22. 22.
    Theodoropoulos N, Ladner DP, Ison MG. Screening recipients of increased-risk donor organs: a survey of transplant infectious diseases physician practices. Transpl Infect Dis. 2013;15(5):545–9.PubMedGoogle Scholar
  23. 23.
    Suryaprasad A, Basavaraju SV, Hocevar SN, Theodoropoulos N, Zuckerman RA, Hayden T, et al. Transmission of hepatitis C virus from organ donors despite nucleic acid test screening. Am J Transplant. 2015;15(7):1827–35.PubMedCrossRefGoogle Scholar
  24. 24.
    Ison MG, Hager J, Blumberg E, Burdick J, Carney K, Cutler J, et al. Donor-derived disease transmission events in the United States: data reviewed by the OPTN/UNOS Disease Transmission Advisory Committee. Am J Transplant. 2009;9(8):1929–35.PubMedCrossRefGoogle Scholar
  25. 25.
    Green M, Covington S, Taranto S, Wolfe C, Bell W, Biggins SW, et al. Donor-derived transmission events in 2013: a report of the Organ Procurement Transplant Network Ad Hoc Disease Transmission Advisory Committee. Transplantation. 2015;99(2):282–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Ramanan P, Deziel PJ, Norby SM, Yao JD, Garza I, Razonable RR. Donor-derived HTLV-1 associated myelopathy after transplantation: a call for targeted screening. Am J Transplant. 2015;15(4):1125.PubMedCrossRefGoogle Scholar
  27. 27.
    Abanyie FA, Gray EB, Delli Carpini KW, Yanofsky A, McAuliffe I, Rana M, et al. Donor-derived strongyloides stercoralis infection in solid organ transplant recipients in the United States, 2009-2013. Am J Transplant. 2015;15(5):1369–75.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Kim SH, Ha YE, Youn JC, Park JS, Sung H, Kim MN, et al. Fatal scedosporiosis in multiple solid organ allografts transmitted from a nearly-drowned donor. Am J Transplant. 2015;15(3):833–40.PubMedCrossRefGoogle Scholar
  29. 29.
    Miceli MH, Gonulalan M, Perri MB, Samuel L, Al Fares MA, Brown K, et al. Transmission of infection to liver transplant recipients from donors with infective endocarditis: lessons learned. Transpl Infect Dis. 2015;17(1):140–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Abbott IJ, Papadakis G, Kaye M, Opdam H, Hutton H, Angus PW, et al. Laboratory identification of donor-derived coxsackievirus b3 transmission. Am J Transplant. 2015;15(2):555–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Gupte AA, Hocevar SN, Lea AS, Kulkarni RD, Schain DC, Casey MJ, et al. Transmission of Balamuthia mandrillaris through solid organ transplantation: utility of organ recipient serology to guide clinical management. Am J Transplant. 2014;14(6):1417–24.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Hocevar SN, Paddock CD, Spak CW, Rosenblatt R, Diaz-Luna H, Castillo I, et al. Microsporidiosis acquired through solid organ transplantation: a public health investigation. Ann Intern Med. 2014;160(4):213–20.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Sachdev SH, Joshi V, Cox ER, Amoroso A, Palekar S. Severe life-threatening Ehrlichia chaffeensis infections transmitted through solid organ transplantation. Transpl Infect Dis. 2014;16(1):119–24.PubMedCrossRefGoogle Scholar
  34. 34.
    Huprikar S, Bosserman E, Patel G, Moore A, Pinney S, Anyanwu A, et al. Donor-derived Trypanosoma cruzi infection in solid organ recipients in the United States, 2001-2011. Am J Transplant. 2013;13(9):2418–25.PubMedCrossRefGoogle Scholar
  35. 35.
    Kumar D, Budev M, Koval C, Hellinger WC, Gordon SM, Tomford JW. Donor-derived tuberculosis (TB) infection in lung transplant despite following recommended algorithm. Am J Transplant. 2013;13(8):2225–6.PubMedCrossRefGoogle Scholar
  36. 36.
    Center for Disease Control and Prevention (CDC). Transmission of Strongyloides stercoralis through transplantation of solid organs—Pennsylvania, 2012. Morb Mortal Wkly Rep. 2013;62(14):264–6.Google Scholar
  37. 37.
    Doucette KE, Al-Saif M, Kneteman N, Chui L, Tyrrell GJ, Kumar D, et al. Donor-derived bacteremia in liver transplant recipients despite antibiotic prophylaxis. Am J Transplant. 2013;13(4):1080–3.PubMedCrossRefGoogle Scholar
  38. 38.
    Dierberg KL, Marr KA, Subramanian A, Nace H, Desai N, Locke JE, et al. Donor-derived organ transplant transmission of coccidioidomycosis. Transpl Infect Dis. 2012;14(3):300–4.PubMedCrossRefGoogle Scholar
  39. 39.
    Freeman RB, Giatras I, Falagas ME, Supran S, O’Connor K, Bradley J, et al. Outcome of transplantation of organs procured from bacteremic donors. Transplantation. 1999;68(8):1107–11.PubMedCrossRefGoogle Scholar
  40. 40.
    Lumbreras C. Bacterial pathogens and donor transmission. In: 3rd international transplant infectious diseases conference. Prague, Czech Republic; 2007.Google Scholar
  41. 41.
    Ruiz I, Gavalda J, Monforte V, Len O, Roman A, Bravo C, et al. Donor-to-host transmission of bacterial and fungal infections in lung transplantation. Am J Transplant. 2006;6(1):178–82.PubMedCrossRefGoogle Scholar
  42. 42.
    Lumbreras C, Sanz F, Gonzalez A, Perez G, Ramos MJ, Aguado JM, et al. Clinical significance of donor-unrecognized bacteremia in the outcome of solid-organ transplant recipients. Clin Infect Dis. 2001;33(5):722–6.PubMedCrossRefGoogle Scholar
  43. 43.
    OPTN Policy 15. Identification of transmissible diseases. https://optn.transplant.hrsa.gov/media/1200/optn_policies.pdf
  44. 44.
    Miller R, Covington S, Taranto S, Carrico R, Ehsan A, Friedman B, et al. Communication gaps associated with donor-derived infections. Am J Transplant. 2015;15(1):259–64.PubMedCrossRefGoogle Scholar
  45. 45.
    Abecassis M, Adams M, Adams P, Arnold RM, Atkins CR, Barr ML, et al. Consensus statement on the live organ donor. JAMA. 2000;284(22):2919–26.PubMedCrossRefGoogle Scholar
  46. 46.
    Avery RK. Recipient screening prior to solid-organ transplantation. Clin Infect Dis. 2002;35(12):1513–9.PubMedCrossRefGoogle Scholar
  47. 47.
    Kasiske BL, Ravenscraft M, Ramos EL, Gaston RS, Bia MJ, Danovitch GM. The evaluation of living renal transplant donors: clinical practice guidelines. Ad Hoc Clinical Practice Guidelines Subcommittee of the Patient Care and Education Committee of the American Society of Transplant Physicians. J Am Soc Nephrol. 1996;7(11):2288–313.PubMedGoogle Scholar
  48. 48.
    Rosendale JD, Chabalewski FL, McBride MA, Garrity ER, Rosengard BR, Delmonico FL, et al. Increased transplanted organs from the use of a standardized donor management protocol. Am J Transplant. 2002;2(8):761–8.PubMedCrossRefGoogle Scholar
  49. 49.
    Rosengard BR, Feng S, Alfrey EJ, Zaroff JG, Emond JC, Henry ML, et al. Report of the Crystal City meeting to maximize the use of organs recovered from the cadaver donor. Am J Transplant. 2002;2(8):701–11.PubMedCrossRefGoogle Scholar
  50. 50.
    Schaffner A. Pretransplant evaluation for infections in donors and recipients of solid organs. Clin Infect Dis. 2001;33 Suppl 1:S9–14.PubMedCrossRefGoogle Scholar
  51. 51.
    Fischer SA, Lu K, Practice AIDCo. Screening of donor and recipient in solid organ transplantation. Am J Transplant 2013;13 Suppl 4:9–21.Google Scholar
  52. 52.
    Bumbacea D, Arend SM, Eyuboglu F, Fishman JA, Goletti D, Ison MG, et al. The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement. Eur Respir J. 2012;40(4):990–1013.PubMedCrossRefGoogle Scholar
  53. 53.
    Chin-Hong PV, Schwartz BS, Bern C, Montgomery SP, Kontak S, Kubak B, et al. Screening and treatment of chagas disease in organ transplant recipients in the United States: recommendations from the chagas in transplant working group. Am J Transplant. 2011;11(4):672–80.PubMedCrossRefGoogle Scholar
  54. 54.
    Levi ME, Kumar D, Green M, Ison MG, Kaul D, Michaels MG, et al. Considerations for screening live kidney donors for endemic infections: a viewpoint on the UNOS policy. Am J Transplant. 2014;14(5):1003–11.PubMedCrossRefGoogle Scholar
  55. 55.
    Huprikar S, Danziger-Isakov L, Ahn J, Naugler S, Blumberg E, Avery RK, et al. Solid organ transplantation from hepatitis B virus-positive donors: consensus guidelines for recipient management. Am J Transplant. 2015;15(5):1162–72.PubMedCrossRefGoogle Scholar
  56. 56.
    Theodoropoulos N, Jaramillo A, Ladner DP, Ison MG. Deceased organ donor screening for HIV, hepatitis B, and hepatitis C viruses: a survey of organ procurement organization practices. Am J Transplant. 2013;13(8):2186–90.PubMedCrossRefGoogle Scholar
  57. 57.
    OPTN Policy 15. Identification of transmissible diseases.Google Scholar
  58. 58.
    Weusten JJ, van Drimmelen HA, Lelie PN. Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window-phase donations not detected by NAT. Transfusion. 2002;42(5):537–48.PubMedCrossRefGoogle Scholar
  59. 59.
    Kleinman S, Busch MP, Korelitz JJ, Schreiber GB. The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection. Transfus Med Rev. 1997;11(3):155–72.PubMedCrossRefGoogle Scholar
  60. 60.
    Kucirka LM, Sarathy H, Govindan P, Wolf JH, Ellison TA, Hart LJ, et al. Risk of window period hepatitis-C infection in high infectious risk donors: systematic review and meta-analysis. Am J Transplant. 2011;11(6):1188–200.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Kucirka LM, Sarathy H, Govindan P, Wolf JH, Ellison TA, Hart LJ, et al. Risk of window period HIV infection in high infectious risk donors: systematic review and meta-analysis. Am J Transplant. 2011;11(6):1176–87.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Eastlund T. Hemodilution due to blood loss and transfusion and reliability of cadaver tissue donor infectious disease testing. Cell Tissue Bank. 2000;1(2):121–7.PubMedCrossRefGoogle Scholar
  63. 63.
    Rose C, Mohr J, Gross M, Lee S. Hemodilution—an overview of current canadian practices. Cell Tissue Bank. 2001;2(1):41–4.PubMedCrossRefGoogle Scholar
  64. 64.
    Guidelines for preventing transmission of human immunodeficiency virus through transplantation of human tissue and organs. Morb Mortal Wkly Rep. 1994;43(RR-8):1–17.Google Scholar
  65. 65.
  66. 66.
    OPTN Policy 2.0 Deceased donor organ procurement. https://optn.transplant.hrsa.gov/media/1200/optn_policies.pdf
  67. 67.
    Bern C, Montgomery SP, Herwaldt BL, Rassi Jr A, Marin-Neto JA, Dantas RO, et al. Evaluation and treatment of chagas disease in the United States: a systematic review. JAMA. 2007;298(18):2171–81.PubMedCrossRefGoogle Scholar
  68. 68.
    Kotton CN. Zoonoses in solid-organ and hematopoietic stem cell transplant recipients. Clin Infect Dis. 2007;44(6):857–66.PubMedCrossRefGoogle Scholar
  69. 69.
    Singh N, Huprikar S, Burdette SD, Morris MI, Blair JE, Wheat LJ, et al. Donor-derived fungal infections in organ transplant recipients: guidelines of the American Society of Transplantation, infectious diseases community of practice. Am J Transplant. 2012;12(9):2414–28.PubMedCrossRefGoogle Scholar
  70. 70.
    Schwartz BS, Mawhorter SD, Practice AIDCo. Parasitic infections in solid organ transplantation. Am J Transplant. 2013;13 Suppl 4:280–303.PubMedCrossRefGoogle Scholar
  71. 71.
    Winston DJ, Vikram HR, Rabe IB, Dhillon G, Mulligan D, Hong JC, et al. Donor-derived West Nile virus infection in solid organ transplant recipients: report of four additional cases and review of clinical, diagnostic, and therapeutic features. Transplantation. 2014;97(9):881–9.PubMedCrossRefGoogle Scholar
  72. 72.
    Nett RJ, Kuehnert MJ, Ison MG, Orlowski JP, Fischer M, Staples JE. Current practices and evaluation of screening solid organ donors for West Nile virus. Transpl Infect Dis. 2012;14(3):268–77.PubMedCrossRefGoogle Scholar
  73. 73.
    Kiberd BA, Forward K. Screening for West Nile virus in organ transplantation: a medical decision analysis. Am J Transplant. 2004;4:1296–301.PubMedCrossRefGoogle Scholar
  74. 74.
    Guidance for recognizing central nervous system infections in potential deceased organ donors: what to consider during donor evaluation and organ offers. https://optn.transplant.hrsa.gov/ContentDocuments/Guidance_DTAC_CNS_Infections.pdf
  75. 75.
    Basavaraju SV, Kuehnert MJ, Zaki SR, Sejvar JJ. Encephalitis caused by pathogens through organ transplants, United States, 2002-2013. Emerg Infect Dis. 2014;20(9):1443–51Google Scholar
  76. 76.
    McNeill KM, Ridgely Benton F, Monteith SC, Tuchscherer MA, Gaydos JC. Epidemic spread of adenovirus type 4-associated acute respiratory disease between U.S. Army installations. Emerg Infect Dis. 2000;6(4):415–9.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Taylor Z, Nolan CM, Blumberg HM. Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. MMWR Recomm Rep. 2005;54(RR-12):1–81.Google Scholar
  78. 78.
    Danziger-Isakov L, Kumar D, Practice AIDCo. Vaccination in solid organ transplantation. Am J Transplant 2013;13 Suppl 4:311–7.Google Scholar
  79. 79.
    Keiser PB, Nutman TB. Strongyloides stercoralis in the immunocompromised population. Clin Microbiol Rev. 2004;17(1):208–17.PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Parasitic infections. Am J Transplant. 2004;4(Suppl 10):142–155.Google Scholar
  81. 81.
    Blair JE, Logan JL. Coccidioidomycosis in solid organ transplantation. Clin Infect Dis. 2001;33(9):1536–44.PubMedCrossRefGoogle Scholar
  82. 82.
    Vail GM, Young RS, Wheat LJ, Filo RS, Cornetta K, Goldman M. Incidence of histoplasmosis following allogeneic bone marrow transplant or solid organ transplant in a hyperendemic area. Transpl Infect Dis. 2002;4(3):148–51.PubMedCrossRefGoogle Scholar
  83. 83.
    LiPuma JJ. Expanding microbiology of pulmonary infection in cystic fibrosis. Pediatr Infect Dis J. 2000;19(5):473–4.PubMedCrossRefGoogle Scholar
  84. 84.
    LiPuma JJ. Burkholderia cepacia complex: a contraindication to lung transplantation in cystic fibrosis? Transpl Infect Dis. 2001;3(3):149–60.PubMedCrossRefGoogle Scholar
  85. 85.
    Arslan M, Wiesner RH, Sievers C, Egan K, Zein NN. Double-dose accelerated hepatitis B vaccine in patients with end-stage liver disease. Liver Transpl. 2001;7(4):314–20.PubMedCrossRefGoogle Scholar
  86. 86.
    Eardley KS, Jones HE, Osman H, Smith SA. Efficacy of the accelerated hepatitis B vaccination schedule used in haemodialysis patients post-exposure to virus: a single-centre experience. Nephrol Dial Transplant. 2002;17(11):1982–7.PubMedCrossRefGoogle Scholar
  87. 87.
    Kallinowski B, Benz C, Buchholz L, Stremmel W. Accelerated schedule of hepatitis B vaccination in liver transplant candidates. Transplant Proc. 1998;30(3):797–9.PubMedCrossRefGoogle Scholar
  88. 88.
    Kucirka LM, Bowring MG, Massie AB, Luo X, Nicholas LH, Segev DL. Landscape of deceased donors labeled increased risk for disease transmission under new guidelines. Am J Transplant. 2015;15(12):3215–23.PubMedPubMedCentralCrossRefGoogle Scholar
  89. 89.
    Schweitzer EJ, Perencevich EN, Philosophe B, Bartlett ST. Estimated benefits of transplantation of kidneys from donors at increased risk for HIV or hepatitis C infection. Am J Transplant. 2007;7(6):1515–25.PubMedCrossRefGoogle Scholar
  90. 90.
    Limaye AP, Connolly PA, Sagar M, Fritsche TR, Cookson BT, Wheat LJ, et al. Transmission of Histoplasma capsulatum by organ transplantation. N Engl J Med. 2000;343(16):1163–6.PubMedCrossRefGoogle Scholar
  91. 91.
    Department of Health and Human Services 42 CFR part 121: organ procurement and transplantation: implementation of the HIV Organ Policy Equity Act. https://www.federalregister.gov/articles/2015/05/08/2015-11048/organ-procurement-and-transplantationimplementation-of-the-hiv-organ-policy-equity-act
  92. 92.
    Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Danziger-Isakov L, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2013;96(4):333–60.PubMedCrossRefGoogle Scholar
  93. 93.
    Razonable RR, Humar A, Practice AIDCo. Cytomegalovirus in solid organ transplantation. Am J Transplant. 2013;13 Suppl 4:93–106.Google Scholar
  94. 94.
    Lim WH, Russ GR, Coates PT. Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation. Nephrology (Carlton). 2006;11(4):355–66.CrossRefGoogle Scholar
  95. 95.
    Green M, Michaels MG. Epstein-Barr virus infection and posttransplant lymphoproliferative disorder. Am J Transplant. 2013;13 Suppl 3:41–54; quiz 54.PubMedCrossRefGoogle Scholar
  96. 96.
    Allen UD, Preiksaitis JK, Practice AIDCo. Epstein-Barr virus and posttransplant lymphoproliferative disorder in solid organ transplantation. Am J Transplant. 2013;13 Suppl 4:107–20.PubMedCrossRefGoogle Scholar
  97. 97.
    Kloster B, Kramer R, Eastlund T, Grossman B, Zarvan B. Hepatitis B surface antigenemia in blood donors following vaccination. Transfusion. 1995;35(6):475–7.PubMedCrossRefGoogle Scholar
  98. 98.
    Ly D, Yee Jr HF, Brezina M, Martin P, Gitnick G, Saab S. Hepatitis B surface antigenemia in chronic hemodialysis patients: effect of hepatitis B immunization. Am J Gastroenterol. 2002;97(1):138–41.PubMedCrossRefGoogle Scholar
  99. 99.
    Chung RT, Feng S, Delmonico FL. Approach to the management of allograft recipients following the detection of hepatitis B virus in the prospective organ donor. Am J Transplant. 2001;1(2):185–91.PubMedCrossRefGoogle Scholar
  100. 100.
    Tung BY, Kowdley KV. Hepatitis B and liver transplantation. Clin Infect Dis. 2005;41(10):1461–6.PubMedCrossRefGoogle Scholar
  101. 101.
    Natov SN. Transmission of viral hepatitis by kidney transplantation: donor evaluation and transplant policies (part 1: hepatitis B virus). Transpl Infect Dis. 2002;4(3):124–31.PubMedCrossRefGoogle Scholar
  102. 102.
    Ouseph R, Eng M, Ravindra K, Brock GN, Buell JF, Marvin MR. Review of the use of hepatitis B core antibody-positive kidney donors. Transplant Rev (Orlando). 2010;24(4):167–71.CrossRefGoogle Scholar
  103. 103.
    Donataccio D, Roggen F, De Reyck C, Verbaandert C, Bodeus M, Lerut J. Use of anti-HBc positive allografts in adult liver transplantation: toward a safer way to expand the donor pool. Transpl Int. 2006;19(1):38–43.PubMedCrossRefGoogle Scholar
  104. 104.
    Loggi E, Micco L, Ercolani G, Cucchetti A, Bihl FK, Grazi GL, et al. Liver transplantation from hepatitis B surface antigen positive donors: a safe way to expand the donor pool. J Hepatol. 2012;56(3):579–85.PubMedCrossRefGoogle Scholar
  105. 105.
    Ghany MG, Strader DB, Thomas DL, Seeff LB, Diseases AAftSoL. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335–74.PubMedCrossRefGoogle Scholar
  106. 106.
    Levitsky J, Doucette K. Viral hepatitis in solid organ transplant recipients. Am J Transplant. 2009;9 Suppl 4:S116–30.PubMedCrossRefGoogle Scholar
  107. 107.
    Kucirka LM, Singer AL, Ros RL, Montgomery RA, Dagher NN, Segev DL. Underutilization of hepatitis C-positive kidneys for hepatitis C-positive recipients. Am J Transplant. 2010;10(5):1238–46.PubMedCrossRefGoogle Scholar
  108. 108.
    Kucirka LM, Peters TG, Segev DL. Impact of donor hepatitis C virus infection status on death and need for liver transplant in hepatitis C virus-positive kidney transplant recipients. Am J Kidney Dis. 2012;60(1):112–20.PubMedCrossRefGoogle Scholar
  109. 109.
    Bucci JR, Lentine KL, Agodoa LY, Peters TG, Schnitzler MA, Abbott KC. Outcomes associated with recipient and donor hepatitis C serology status after kidney transplantation in the United States: analysis of the USRDS/UNOS database. Clin Transpl. 2004:51–61.Google Scholar
  110. 110.
    Gasink LB, Blumberg EA, Localio AR, Desai SS, Israni AK, Lautenbach E. Hepatitis C virus seropositivity in organ donors and survival in heart transplant recipients. JAMA. 2006;296(15):1843–50.PubMedCrossRefGoogle Scholar
  111. 111.
    Lake KD, Smith CI, Milfred-La Forest SK, Pritzker MR, Emery RW. Outcomes of hepatitis C positive (HCV+) heart transplant recipients. Transplant Proc. 1997;29(1–2):581–2.PubMedCrossRefGoogle Scholar
  112. 112.
    Ong JP, Barnes DS, Younossi ZM, Gramlich T, Yen-Lieberman B, Goormastic M, et al. Outcome of de novo hepatitis C virus infection in heart transplant recipients. Hepatology. 1999;30(5):1293–8.PubMedCrossRefGoogle Scholar
  113. 113.
    Wendt JM, Kaul D, Limbago BM, Ramesh M, Cohle S, Denison AM, et al. Transmission of methicillin-resistant Staphylococcus aureus infection through solid organ transplantation: confirmation via whole genome sequencing. Am J Transplant. 2014;14(11):2633–9.PubMedPubMedCentralCrossRefGoogle Scholar
  114. 114.
    Ison MG, Grossi P, Practice AIDCo. Donor-derived infections in solid organ transplantation. Am J Transplant. 2013;13 Suppl 4:22–30.Google Scholar
  115. 115.
    Issa NC, Patel R. Potential for expansion of the donor pool using liver allografts from donors with bacterial meningitis. Liver Transpl. 2002;8(10):977–9.PubMedCrossRefGoogle Scholar
  116. 116.
    Lopez-Navidad A, Domingo P, Caballero F, Gonzalez C, Santiago C. Successful transplantation of organs retrieved from donors with bacterial meningitis. Transplantation. 1997;64(2):365–8.PubMedCrossRefGoogle Scholar
  117. 117.
    Paig i JM, Lopez-Navidad A, Lloveras J, Mir M, Orfila A, Quintana S. Organ donors with adequately treated bacterial meningitis may be suitable for successful transplantation. Transplant Proc. 2000;32(1):75–7.PubMedCrossRefGoogle Scholar
  118. 118.
    Satoi S, Bramhall SR, Solomon M, Hastings M, Mayer AD, de Goyet JV, et al. The use of liver grafts from donors with bacterial meningitis. Transplantation. 2001;72(6):1108–13.PubMedCrossRefGoogle Scholar
  119. 119.
    Theodoropoulos N, Jaramillo A, Penugonda S, Wasik C, Brooks K, Ladner DP, et al. Improving syphilis screening in deceased organ donors. Transplantation. 2015;99(2):438–43.PubMedCrossRefGoogle Scholar
  120. 120.
    Caballero F, Domingo P, Rabella N, Lopez-Navidad A. Successful transplantation of organs retrieved from a donor with syphilis. Transplantation. 1998;65(4):598–9.PubMedCrossRefGoogle Scholar
  121. 121.
    Gibel LJ, Sterling W, Hoy W, Harford A. Is serological evidence of infection with syphilis a contraindication to kidney donation? Case report and review of the literature. J Urol. 1987;138(5):1226–7.PubMedGoogle Scholar
  122. 122.
    Ko WJ, Chu SH, Lee YH, Lee PH, Lee CJ, Chao SH, et al. Successful prevention of syphilis transmission from a multiple organ donor with serological evidence of syphilis. Transplant Proc. 1998;30(7):3667–8.PubMedCrossRefGoogle Scholar
  123. 123.
    Anderson CB, Haid SD, Hruska KA, Etheredge EA. Significance of microbial contamination of stored cadaver kidneys. Arch Surg. 1978;113(3):269–71.PubMedCrossRefGoogle Scholar
  124. 124.
    McCoy GC, Loening S, Braun WE, Magnusson MO, Banowsky LH, McHenry MC. The fate of cadaver renal allografts contaminated before transplantation. Transplantation. 1975;20(6):467–72.PubMedCrossRefGoogle Scholar
  125. 125.
    Mossad SB, Avery RK, Goormastic M, Hobbs RE, Stewart RW. Significance of positive cultures from donor left atrium and postpreservation fluid in heart transplantation. Transplantation. 1997;64(8):1209–10.PubMedCrossRefGoogle Scholar
  126. 126.
    Subramanian AK, Morris MI, Practice AIDCo. Mycobacterium tuberculosis infections in solid organ transplantation. Am J Transplant. 2013;13 Suppl 4:68–76.PubMedCrossRefGoogle Scholar
  127. 127.
    Morris MI, Daly JS, Blumberg E, Kumar D, Sester M, Schluger N, et al. Diagnosis and management of tuberculosis in transplant donors: a donor-derived infections consensus conference report. Am J Transplant. 2012;12(9):2288–300.PubMedCrossRefGoogle Scholar
  128. 128.
    Graham JC, Kearns AM, Magee JG, El-Sheikh MF, Hudson M, Manas D, et al. Tuberculosis transmitted through transplantation. J Infect. 2001;43(4):251–4.PubMedCrossRefGoogle Scholar
  129. 129.
    Nagai S, Fujimoto Y, Taira K, Egawa H, Takada Y, Kiuchi T, et al. Liver transplantation without isoniazid prophylaxis for recipients with a history of tuberculosis. Clin Transplant. 2007;21(2):229–34.PubMedCrossRefGoogle Scholar
  130. 130.
    Peters TG, Reiter CG, Boswell RL. Transmission of tuberculosis by kidney transplantation. Transplantation. 1984;38(5):514–6.PubMedCrossRefGoogle Scholar
  131. 131.
    Winthrop KL, Kubak BM, Pegues DA, Hufana C, Costamagna P, Desmond E, et al. Transmission of mycobacterium tuberculosis via lung transplantation. Am J Transplant. 2004;4(9):1529–33.PubMedCrossRefGoogle Scholar
  132. 132.
    Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis. 1998;27(5):1266–77.PubMedCrossRefGoogle Scholar
  133. 133.
    Mazurek GH, Jereb J, Lobue P, Iademarco MF, Metchock B, Vernon A. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 2005;54(RR-15):49–55.Google Scholar
  134. 134.
    Gourishankar S, Doucette K, Fenton J, Purych D, Kowalewska-Grochowska K, Preiksaitis J. The use of donor and recipient screening for toxoplasma in the era of universal trimethoprim sulfamethoxazole prophylaxis. Transplantation. 2008;85(7):980–5.PubMedCrossRefGoogle Scholar
  135. 135.
    Derouin F, Pelloux H. Prevention of toxoplasmosis in transplant patients. Clin Microbiol Infect. 2008;14(12):1089–101.PubMedCrossRefGoogle Scholar
  136. 136.
    Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion. 2002;42:975–9.PubMedCrossRefGoogle Scholar
  137. 137.
    Jackson BR, Busch MP, Stramer SL, Au Buchon JP. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole blood donations. Transfusion. 2003;43:721–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Internal Medicine/Infectious DiseasesThe Ohio State UniversityColumbusUSA
  2. 2.Divisions of Infectious Diseases and OrganTransplantationNorthwestern University Feinberg School of MedicineChicagoUSA

Personalised recommendations